Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Precision cancer medicine: Concepts, current practice, and future developments.
Edsjö A, Holmquist L, Geoerger B, Nowak F, Gomon G, Alix-Panabières C, Ploeger C, Lassen U, Le Tourneau C, Lehtiö J, Ott PA, von Deimling A, Fröhling S, Voest E, Klauschen F, Dienstmann R, Alshibany A, Siu LL, Stenzinger A. Edsjö A, et al. Among authors: lassen u. J Intern Med. 2023 Oct;294(4):455-481. doi: 10.1111/joim.13709. Epub 2023 Aug 28. J Intern Med. 2023. PMID: 37641393 Review.
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Taskén K, F Haj Mohammad S, Fagereng GL, Sørum Falk R, Helland Å, Barjesteh van Waalwijk van Doorn-Khosrovani S, Steen Carlsson K, Ryll B, Jalkanen K, Edsjö A, Russnes HG, Lassen U, Hallersjö Hult E, Lugowska I, Blay JY, Verlingue L, Abel E, Lowery MA, Krebs MG, Staal Rohrberg K, Ojamaa K, Oliveira J, Verheul HMW, Voest EE, Gelderblom H; PRIME-ROSE Consortium and the PCM4EU Consortium. Taskén K, et al. Among authors: lassen u. Acta Oncol. 2024 May 23;63:385-391. doi: 10.2340/1651-226X.2024.34791. Acta Oncol. 2024. PMID: 38779910 Free PMC article.
Overcoming barriers in biomarker testing. Letter to the Editor regarding: 'ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe', by A. Bayle et al.
García-Foncillas J, Arnold D, Avouac B, Lassen U, Laurent-Puig P, Taieb J, Helland Å, Stenzinger A. García-Foncillas J, et al. Among authors: lassen u. Ann Oncol. 2024 Jul;35(7):677-678. doi: 10.1016/j.annonc.2024.04.008. Epub 2024 May 7. Ann Oncol. 2024. PMID: 38723866 No abstract available.
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition.
Borch A, Carri I, Reynisson B, Alvarez HMG, Munk KK, Montemurro A, Kristensen NP, Tvingsholm SA, Holm JS, Heeke C, Moss KH, Hansen UK, Schaap-Johansen AL, Bagger FO, de Lima VAB, Rohrberg KS, Funt SA, Donia M, Svane IM, Lassen U, Barra C, Nielsen M, Hadrup SR. Borch A, et al. Among authors: lassen u. Front Immunol. 2024 Apr 3;15:1360281. doi: 10.3389/fimmu.2024.1360281. eCollection 2024. Front Immunol. 2024. PMID: 38633261 Free PMC article.
Magnetic resonance imaging and o-(2-[18F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.
Henriksen OM, Maarup S, Hasselbalch B, Poulsen HS, Christensen IJ, Madsen K, Larsen VA, Lassen U, Law I. Henriksen OM, et al. Among authors: lassen u. Neurooncol Adv. 2024 Oct 24;6(1):vdae178. doi: 10.1093/noajnl/vdae178. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39659835 Free PMC article.
208 results